Navigation Links
NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership
Date:1/19/2009

SAN DIEGO, Jan. 19 /PRNewswire/ -- NexBio announces the completion of its First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug candidate for influenza. The single-dose, escalating Phase I study completed in December 2008 was designed to assess DAS181 safety in healthy subjects. The study drug was well tolerated at all dose levels. DAS181 is a novel broad-spectrum drug candidate for prophylaxis and treatment of respiratory infections by all variations of influenza virus, including the types of the virus that may cause a potential influenza pandemic. In addition, DAS181 also has the potential for prophylaxis and treatment of influenza-like illness due to other respiratory viruses, including the parainfluenza virus which may cause serious respiratory illness similar to influenza for which there is no approved vaccine or therapeutic. The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

DAS181, a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and parainfluenza viruses from infecting the human body or from amplifying in infected individuals. DAS181 effectively inhibits numerous strains of influenza and parainfluenza virus in cell culture and in animal models. Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with the currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance.

To strengthen DAS181 clinical development, NexBio announces the hiring of Ronald B. Moss, M.D., as NexBio's Executive Vice President of Clinical Development & Medical Affairs. Dr. Moss brings 22 years of research and clinical experience, including 15 y
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NexBio to Present at 2007 BIOCOM Investor Conference
2. Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered
3. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
4. InSet Technologies Completes $25 Million Financing
5. AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
6. Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC
7. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
8. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
9. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
10. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
11. Hard To Treat Diseases (HTDS) Completes E Europe Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Pro3rd Impression is ... for Final Cut Pro X. Pro3rd Impression's clean and ... , Intuitive on-screen-controls allow users to customize scale, position ... layouts, and much more can be edited using the ... Pro3rd Impression comes packed with 30 simplistically elegant ...
(Date:5/21/2015)... May 21, 2015 WellCare Health Plans, Inc. ... been selected by the Florida Healthy Kids Corporation (FHKC) to ... of age, as part of the Florida Healthy Kids (FHK) ... 1, 2015, and may be extended for two additional years ... serve children in the FHK program who live in Regions ...
(Date:5/21/2015)... ChiliPad is a temperature-regulated mattress pad ... the bed so that users sleep comfortably all night ... bed can pick their ideal sleep temperature and maintain ... stay asleep longer. , Unlike other products, ChiliPad uses ... which produces a more concentrated temperature than circulated air. ...
(Date:5/21/2015)... The ThedaCare Center for Healthcare Value welcomes long-time ... president. Barnas is based in Appleton to support operations as ... lead and support Center teams that are working to help ... patient experience , Making quality more transparent ... , The Center is excited to bring Barnas’s knowledge ...
(Date:5/21/2015)... 2015 Shimadzu Scientific Instruments today ... which features new time-saving tools to maximize laboratory ... liquid, headspace, and solid-phase microextraction (SPME), the AOC-6000 ... allows users to seamlessly change injection techniques before ... The new autosampler allows for sample preparation to ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2Health News:WellCare Selected to Continue Participating in the Florida Healthy Kids Program, Will Serve Nine Florida Regions Under the New Contract 2Health News:ChiliPad, a Dual-Zone Temperature-Controlled Mattress Pad, Promotes Better Sleep, Health Benefits, and Saves on Cooling Costs in Upcoming Hot Summer Weather 2Health News:ChiliPad, a Dual-Zone Temperature-Controlled Mattress Pad, Promotes Better Sleep, Health Benefits, and Saves on Cooling Costs in Upcoming Hot Summer Weather 3Health News:Kim Barnas joins ThedaCare Center for Healthcare Value 2Health News:Shimadzu’s New AOC-6000 Autosampler Makes Automated Sample Introduction Simple and Efficient 2
... can enjoy some Halloween candy and still avoid sugar-related tooth ... Mitchell said the key to preventing tooth decay lies in ... also how long the sugar remains in the mouth. ... keep harmful bacteria from developing, she said, and eating the ...
... (HealthDay News) -- Halloween candy may contain some obvious ... asthma triggers that can pose a threat to trick-or-treaters, ... experts from the American College of Allergy, Asthma and ... they focus on candy and often overlook many other ...
... a 320 detector row CT scanner found that a contrast ... enhancement in more than 96% of coronary segments," said Frank ... one of the authors of the study. "Many ... to 80 milliliters of iopamidol," he said. The study ...
... Today, the results from a European Survey of Oncology ... first time at The European Multidisciplinary Cancer Congress in ... Pain Initiative, a European Oncology Nursing Society (EONS) working ... to sub-optimal treatment , The survey which collected ...
... throughout the second half of the twentieth century. Experts ... such as the advice of healthcare professionals, longer maternity ... level of education. "Up until not long ... things have changed in the second half of the ...
... J. Snyder, Ph.D., vice president of research for Lifespan ( ... during the annual ceremony last night at Harvard University. ... of Melbourne and Yale Medical School, were recognized for their ... bladder can have the same impact on impairing cognitive function ...
Cached Medicine News:Health News:Halloween Trappings Can Trigger Asthma, Allergies 2Health News:Identification and management of breakthrough cancer pain remains a challenge 2Health News:Identification and management of breakthrough cancer pain remains a challenge 3Health News:Woman with a higher social standing and educational attainment breastfeed for longer 2Health News:Lifespan researcher wins Ig Nobel Prize 2
(Date:5/21/2015)... 2015  Heidrick & Struggles (Nasdaq: HSII ), ... leadership consulting and culture shaping worldwide, ... practices announcing the addition of Tim Dietlin ... Dietlin has extensive life sciences and ... R&D, Medical and Commercial functions to increase productivity, drive ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 /PRNewswire-USNewswire/ ... of physicians who prescribe biologics – Alliance ... Endocrinologists, American College of Rheumatology, Biologics Prescribers ... Rheumatology Organizations, Endocrine Society, and North American ... – sent a letter to U.S. Food ...
(Date:5/21/2015)... , May 21, 2015 Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for cancer, announced today ... Officer of the Company, will be making a presentation ... Emerging Approaches to Immunotherapy at 11:40 a.m. on May 21, ... City . Dr. Bosch,s presentation ...
Breaking Medicine Technology:Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy 2NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy 3
For the determination of urea nitrogen in human serum....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... first microplate spectrophotometer designed specifically to run ... week. With rugged hardware, proven optical performance ... barrier of traditional spectrophotometry to obtain results ... easily read up to eight, 1 cm ...
Medicine Products: